Protocol summary

Study aim
To determine the effect of acupressure on physical and psychological outcomes in patients with multiple sclerosis.
Design
A single-blind, parallel-group, randomized controlled trial with a block randomization design (block size of 4). The target sample size is 70 participants (35 per group). Randomization will be stratified by age at diagnosis and gender. Allocation concealment will be performed using sequentially numbered, sealed opaque envelopes.
Settings and conduct
Eligible patients will be recruited and randomly allocated to either the intervention or control group. The intervention group will receive acupressure training in a face-to-face session and perform the technique at home for 4 weeks, with follow-up via social network (Soroush app) or telephone calls. Outcomes (depression, anxiety, fatigue, sleep quality, and quality of life) will be assessed using validated questionnaires (Beck Depression Inventory, Spielberger State-Trait Anxiety Inventory, Fatigue Severity Scale, Pittsburgh Sleep Quality Index, and SF-36) at baseline and immediately after the 4-week intervention period.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Age 18-50 years; confirmed diagnosis of MS for at least one year;... Exclusion criteria: Inconsistent completion of acupressure sessions;...
Intervention groups
Intervention group: Patients perform acupressure on three acupoints (HT-7/Shenmen, Ki-3, and Yintang/Third Eye) for 4 weeks, three times per week Control group: Patients receive no acupressure intervention and continue their routine care.
Main outcome variables
Mean change in depression score (Beck Depression Inventory) Mean change in anxiety score (Spielberger State-Trait Anxiety Inventory) Mean change in fatigue score (Fatigue Severity Scale) Mean change in sleep quality score (Pittsburgh Sleep Quality Index) Mean change in quality of life score (SF-36 Questionnaire)

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20260630070019N2
Registration date: 2026-08-10, 1405/05/19
Registration timing: retrospective

Last update: 2026-08-10, 1405/05/19
Update count: 0
Registration date
2026-08-10, 1405/05/19
Registrant information
Name
Faezeh Abadi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 71 5335 0994
Email address
faeze.abadi@yahoo.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2018-12-22, 1397/10/01
Expected recruitment end date
2020-03-01, 1398/12/11
Actual recruitment start date
2018-12-22, 1397/10/01
Actual recruitment end date
2020-03-01, 1398/12/11
Trial completion date
2020-03-01, 1398/12/11
Scientific title
The Effect of Acupressure on Physical and Psychological Problems in Multiple Sclerosis Patients
Public title
Effect of Acupressure in Multiple Sclerosis Patients
Purpose
Supportive
Inclusion/Exclusion criteria
Inclusion criteria:
Age between 18 and 50 years. Definite diagnosis of Multiple Sclerosis (MS) for at least one year. Not being in the acute relapse or progressive phase of the disease. No other acute or chronic physical, mental, or psychological disorders. No history of acupressure therapy. Not taking sedatives, antidepressants, hypnotics, or anxiolytic medications. Being conscious and alert. Stable hemodynamic status. No local skin problems at acupoints (e.g., wound, burn, abscess, cyst). No history of substance abuse. Providing written informed consent. Pittsburgh Sleep Quality Index score greater than 5. Literacy (at least 6 years of education) to complete the Beck questionnaire. No visual or auditory impairments.
Exclusion criteria:
Inconsistent or non-completion of acupressure sessions. Withdrawal of consent to continue participation in the study. Development of a serious physical or psychological disorder during the study.
Age
From 18 years old to 50 years old
Gender
Both
Phase
N/A
Groups that have been masked
  • Data analyser
Sample size
Target sample size: 70
More than 1 sample in each individual
Number of samples in each individual: 2
In two stages 1.before and 2. after the intervention
Actual sample size reached: 70
More than 1 sample in each individual
Actual sample size in each individual: 2
In two stages 1.before and 2. after the intervention
Randomization (investigator's opinion)
Randomized
Randomization description
Method of randomization: Block randomization with a block size of 4. In this method, each block contains an equal number of allocations to the intervention and control groups (two participants per group per block). This ensures that the sample sizes in both groups remain balanced throughout the recruitment process. Unit of randomization: The unit of randomization is the individual patient. Randomization strata: This study uses stratification to ensure comparability between groups at baseline. The participants will be stratified (matched) based on the following variables: Age at diagnosis Gender This means that within each stratum (e.g., "males aged 30-40"), separate block randomization sequences will be generated to ensure that these key confounding variables are equally distributed between the intervention and control groups.
Blinding (investigator's opinion)
Single blinded
Blinding description
In this trial, the blinding is designed as a single-blind study. Specifically, the data analyst will be blinded to the group allocation (intervention or control) of the participants. This blinding will be maintained throughout the entire data analysis phase until the final statistical interpretations are completed. Due to the nature of the intervention (acupressure performed by patients themselves at home), it is not feasible to blind the participants or the trainer who teaches the technique. However, to minimize the risk of bias in the analytical phase—one of the most critical stages of the research—the data analyst will remain unaware of the group identities. The data will be provided to the analyst using numerical codes, and the allocation key will not be disclosed to them until all statistical analyses are finalized. This approach ensures objective and unbiased data interpretation.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Fasa university of medical science
Street address
Ebn sina square
City
Fasa
Province
Fars
Postal code
۷۴۶۱۶-۸۶۶۸۸
Approval date
2019-11-29, 1398/09/08
Ethics committee reference number
IR.FUMS.REC.1398.042

Health conditions studied

1

Description of health condition studied
Multiple Sclerosis (MS) is a chronic autoimmune disorder of the central nervous system. In this condition, the immune system attacks the protective myelin sheath surrounding nerve fibers in the brain, optic nerves, and spinal cord .
ICD-10 code
G35
ICD-10 code description
Multiple sclerosis

Primary outcomes

1

Description
Mean score of depression as measured by the Beck Depression Inventory (BDI). This 21-item self-report instrument measures the severity of depressive symptoms over the past two weeks. Each item is scored from 0 to 3, with total scores ranging from 0 to 63. Higher scores indicate greater severity of depression. The primary outcome is the mean change in BDI score from baseline to post-intervention.
Timepoint
Baseline (before the start of the intervention) and immediately after the 4-week intervention period (Week 4).
Method of measurement
Beck Depression Inventory (BDI) - a 21-item self-report questionnaire.

2

Description
Mean score of anxiety as measured by the Spielberger State-Trait Anxiety Inventory (STAI) - Trait scale. This 20-item self-report instrument measures the general tendency to experience anxiety across different situations. Each item is scored from 1 to 4, with total scores ranging from 20 to 80. Higher scores indicate higher levels of anxiety. The primary outcome is the mean change in STAI score from baseline to post-intervention.
Timepoint
Baseline (before the start of the intervention) and immediately after the 4-week intervention period (Week 4).
Method of measurement
Spielberger State-Trait Anxiety Inventory (STAI) - Trait scale, a 20-item self-report questionnaire.

3

Description
Mean score of fatigue as measured by the Fatigue Severity Scale (FSS). This 9-item self-report instrument assesses the severity of fatigue and its impact on daily functioning. Each item is scored from 1 to 7, with the total score calculated as the mean of all items. Total scores range from 1 to 7, with higher scores indicating greater fatigue severity. The primary outcome is the mean change in FSS score from baseline to post-intervention.
Timepoint
Baseline (before the start of the intervention) and immediately after the 4-week intervention period (Week 4).
Method of measurement
Fatigue Severity Scale (FSS) - a 9-item self-report questionnaire.

4

Description
Mean score of sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI). This 19-item self-report instrument assesses sleep quality and disturbances over a one-month period across seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each domain is scored from 0 to 3, with a global PSQI score ranging from 0 to 21. A global score of 5 or higher indicates poor sleep quality. The primary outcome is the mean change in PSQI global score from baseline to post-intervention.
Timepoint
Baseline (before the start of the intervention) and immediately after the 4-week intervention period (Week 4).
Method of measurement
Pittsburgh Sleep Quality Index (PSQI) - a 19-item self-report questionnaire.

5

Description
Mean score of quality of life as measured by the SF-36 Health Survey Questionnaire. This 36-item self-report instrument assesses health-related quality of life across eight domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored from 0 to 100, with higher scores indicating better quality of life. Domain scores are aggregated into two summary component scores: Physical Component Summary (PCS) and Mental Component Summary (MCS). The primary outcome is the mean change in SF-36 domain scores from baseline to post-intervention.
Timepoint
Baseline (before the start of the intervention) and immediately after the 4-week intervention period (Week 4).
Method of measurement
SF-36 Health Survey Questionnaire - a 36-item self-report questionnaire.

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: Patients in this group receive acupressure training and perform the technique at home for 4 weeks. The acupressure is applied on three acupoints: HT-7 (Shenmen point), Ki-3 (Taixi point), and Yintang (Third Eye point). The intervention is performed three times per week (Saturdays, Mondays, and Wednesdays) for 4 consecutive weeks. For HT-7 and Ki-3 points, patients use specialized acupressure bracelets and ankle bands that apply continuous pressure for 30 minutes at each point. For the Yintang point, patients use their thumb or index finger to apply pressure for 10 minutes. The technique is taught in a single face-to-face session by an expert in acupressure therapy, and educational pamphlets are provided for home use. Patients receive daily reminders through a social network application (Soroush) or telephone calls to ensure adherence. The intervention aims to reduce depression, anxiety, fatigue, and improve sleep quality and quality of life in patients with multiple sclerosis.
Category
Other

2

Description
Control group: Patients in this group do not receive any acupressure intervention. They continue to receive their routine standard care and medical treatments as prescribed by their physicians. No specific behavioral intervention is provided during the 4-week study period. However, at the end of the study, if the acupressure technique proves to be effective, the control group participants will be offered the opportunity to receive the acupressure training as an ethical consideration.
Category
Other

Recruitment centers

1

Recruitment center
Name of recruitment center
Multiple Sclerosis Association of Fasa City
Full name of responsible person
Faezeh Abadi
Street address
Ebn sina square
City
Fasa
Province
Fars
Postal code
۷۴۶۱۶-۸۶۶۸۸
Phone
+98 71 5335 0994
Email
faeze.abadi@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Fasa University of Medical Sciences
Full name of responsible person
Faezeh Abadi
Street address
Ebn sina square
City
Fasa
Province
Fars
Postal code
۷۴۶۱۶-۸۶۶۸۸
Phone
+98 71 5335 0994
Email
faeze.abadi@yahoo.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Fasa University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Fasa University of Medical Sciences
Full name of responsible person
Faezeh Abadi
Position
assistant Professor
Latest degree
Ph.D.
Other areas of specialty/work
Nursery
Street address
Ebn sina square
City
Fasa
Province
Fars
Postal code
۷۴۶۱۶-۸۶۶۸۸
Phone
+98 71 5335 0994
Email
faeze.abadi@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Fasa University of Medical Sciences
Full name of responsible person
zhila fereydoni
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Nursery
Street address
Ebn sina square
City
Fasa
Province
Fars
Postal code
۷۴۶۱۶-۸۶۶۸۸
Phone
+98 71 5335 0994
Email
faeze.abadi@yahoo.com

Person responsible for updating data

Contact
Name of organization / entity
Fasa University of Medical Sciences
Full name of responsible person
Faezeh Abadi
Position
Assistant professor
Latest degree
Ph.D.
Other areas of specialty/work
Nursery
Street address
Ebn sina squer
City
Fasa
Province
Fars
Postal code
۷۴۶۱۶-۸۶۶۸۸
Phone
+98 71 5335 0994
Fax
Email
faeze.abadi@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
De-identified individual participant data (all collected outcome measures).
When the data will become available and for how long
6 months after publication, available for 5 years.
To whom data/document is available
Researchers from academic institutions.
Under which criteria data/document could be used
Approved research proposal and signed data sharing agreement.
From where data/document is obtainable
Principal Investigator via email.
What processes are involved for a request to access data/document
Submit request → Review by PI and ethics committee (4-6 weeks) → Sign agreement → Data transfer. Total: 3-4 months.
Comments
Requests reviewed case by case.
Loading...